Women with PMOS Need Regular NHS Screenings, New Guidance Advises

Women with PMOS should have yearly – The National Institute for Health and Care Excellence (NICE) has issued updated recommendations urging healthcare professionals to conduct annual assessments for women diagnosed with polyendocrine metabolic ovarian syndrome (PMOS). This guidance highlights the importance of early detection and consistent monitoring to address the diverse health complications linked to the condition, which affects approximately one in eight women in the UK. Previously referred to as polycystic ovary syndrome (PCOS), the condition was renamed in May to better reflect its broader systemic effects beyond the ovaries.

Redefining the Condition for Better Understanding

PMOS is now recognized as a multifaceted disorder that influences multiple bodily systems, not just reproductive health. The NICE draft guidance emphasizes that the name change aims to capture the condition’s impact on metabolism, hormones, and other physiological processes. This shift underscores the need for a more comprehensive approach to diagnosis and treatment, particularly for women experiencing symptoms that extend beyond typical menstrual irregularities or fertility challenges.

Common Symptoms and Rising Awareness

According to the NHS, the primary indicators of PMOS include irregular or absent menstrual cycles, challenges with conception, facial and body hair overgrowth, weight gain, and hair thinning. Additional symptoms may involve oily skin, acne, and metabolic complications such as diabetes or heart disease. Despite affecting an estimated three to four million women in the UK, PMOS remains under-diagnosed and inconsistently managed, as noted by NICE. The new guidance seeks to address these gaps by promoting standardized care and greater recognition of the condition’s complexity.

Marie Anne Ledingham, NICE’s consultant clinical advisor for women’s and reproductive health, stated that recommending regular annual reviews is a critical step in improving care consistency. “This new guideline will help raise awareness of PMOS and ensure earlier diagnosis and management,” she explained. The revised framework also encourages healthcare providers to consider ethnic factors, as the condition appears more prevalent in women of Black, Asian, and mixed heritage. This insight highlights the need for culturally informed assessments and tailored interventions.

Personal Stories Highlight the Need for Earlier Diagnosis

Sharon Manship, a 30-year PMOS patient, shared her experience of waiting over a decade to receive a definitive diagnosis. “I struggled to get support in my early 20s, and it wasn’t until my mid-30s that I was finally told I had PMOS,” she said. Sharon was part of the committee that developed the new guidelines, and her journey reflects the frustration many women face when their symptoms are dismissed as normal variations of womanhood. “My hope is that this new approach will ensure people with PMOS are taken seriously from the start,” she added, emphasizing the importance of timely and evidence-based care.

“It was so disheartening to be told, until I was finally diagnosed in my mid-30s, that my symptoms were just part of being a woman,” Sharon said. “My hope is that with this new guideline, people with PMOS will be taken seriously, diagnosed earlier, and provided with evidence-based support and care from healthcare professionals from the outset.”

Diagnosis and Management Strategies

Doctors may use blood tests to evaluate hormone levels and ultrasound scans to identify ovarian follicles in suspected cases. However, the new guidance stresses the need for more proactive screening and better integration of these diagnostic tools. While there is no cure for PMOS, the NHS offers treatments to manage symptoms, including hormone therapy and fertility medications. The guidelines also clarify that laser and light therapies for hair reduction are not currently recommended due to their higher costs compared to alternative options.

For women planning a pregnancy, the guidance includes recommendations on weight management, balanced nutrition, exercise, sleep, and mental health support. These aspects are crucial, as PMOS can significantly affect fertility and overall well-being. The condition is a leading cause of female infertility, and addressing its long-term risks—such as metabolic disorders and cardiovascular concerns—is central to the updated recommendations.

Addressing Mental Health and Quality of Life

Living with PMOS can take a toll on mental health, with depression and anxiety being common among affected individuals. The draft guidelines acknowledge this impact and encourage healthcare providers to incorporate mental health assessments into routine evaluations. This holistic approach aims to improve not only physical health outcomes but also the emotional and psychological well-being of patients.

The new guidance also emphasizes that PMOS should not be overlooked in post-menopausal women. This is a significant shift from previous practices, which often assumed the condition was limited to younger populations. By extending diagnostic considerations to all age groups, NICE seeks to ensure that women at every stage of life receive appropriate care.

Consultation Period and Final Steps

The draft guidelines are currently open for public and professional feedback from 1 July to 11 August 2026. During this period, healthcare professionals, patients, and the general public can contribute their insights to shape the final version. The final guidance is expected to be published in December 2026, marking a pivotal moment in the management of PMOS across the NHS.

Experts hope the updated recommendations will lead to a more proactive healthcare system, reducing delays in diagnosis and ensuring that women with PMOS receive consistent, evidence-based support. The emphasis on annual screenings and broader risk assessment aims to create a framework that addresses both immediate symptoms and long-term health challenges. As the consultation period progresses, the goal is to refine these guidelines further and prepare for their implementation in 2026.

For those affected by PMOS, the guidance offers a pathway to more accurate diagnosis and tailored treatment. The NICE recommendations aim to empower women with the knowledge to advocate for their health and ensure that healthcare providers are equipped to recognize and manage the condition effectively. With a focus on early intervention and comprehensive care, the new guidelines represent a significant advancement in addressing the complexities of PMOS for millions of women across the UK.